MX2022015109A - Tratamiento de homocistinuria e hiperhomocisteinemia mediante el uso de cistationina-gamma-liasa. - Google Patents

Tratamiento de homocistinuria e hiperhomocisteinemia mediante el uso de cistationina-gamma-liasa.

Info

Publication number
MX2022015109A
MX2022015109A MX2022015109A MX2022015109A MX2022015109A MX 2022015109 A MX2022015109 A MX 2022015109A MX 2022015109 A MX2022015109 A MX 2022015109A MX 2022015109 A MX2022015109 A MX 2022015109A MX 2022015109 A MX2022015109 A MX 2022015109A
Authority
MX
Mexico
Prior art keywords
hyperhomocysteinemia
cystathionine
lyase
gamma
homocystinuria
Prior art date
Application number
MX2022015109A
Other languages
English (en)
Inventor
Scott W Rowlinson
Leslie Sloan
Christopher Daige
Original Assignee
Aeglea Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeglea Biotherapeutics Inc filed Critical Aeglea Biotherapeutics Inc
Publication of MX2022015109A publication Critical patent/MX2022015109A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y404/00—Carbon-sulfur lyases (4.4)
    • C12Y404/01—Carbon-sulfur lyases (4.4.1)
    • C12Y404/01001—Cystathionine gamma-lyase (4.4.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente divulgación se refiere en general a métodos para tratar pacientes que padecen homocistinuria e hiperhomocisteinemia con enzimas cistationina-gamma-liasa (CGL).
MX2022015109A 2020-05-29 2020-05-29 Tratamiento de homocistinuria e hiperhomocisteinemia mediante el uso de cistationina-gamma-liasa. MX2022015109A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2020/035297 WO2021242258A1 (en) 2020-05-29 2020-05-29 Treatment of homocystinuria and hyperhomocysteinemia using cystathionine-gamma-lyase

Publications (1)

Publication Number Publication Date
MX2022015109A true MX2022015109A (es) 2023-03-17

Family

ID=78745140

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015109A MX2022015109A (es) 2020-05-29 2020-05-29 Tratamiento de homocistinuria e hiperhomocisteinemia mediante el uso de cistationina-gamma-liasa.

Country Status (10)

Country Link
US (1) US20240058429A1 (es)
EP (1) EP4157331A4 (es)
JP (1) JP2023535537A (es)
KR (1) KR20230047335A (es)
CN (1) CN117881418A (es)
AU (1) AU2020449880A1 (es)
BR (1) BR112022024329A2 (es)
CA (1) CA3180781A1 (es)
MX (1) MX2022015109A (es)
WO (1) WO2021242258A1 (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019023800A2 (pt) * 2017-05-12 2020-07-28 Board Of Regents, The University Of Texas System depleção mediada por enzima humana de homocisteína para tratar pacientes com hiperhomocisteinemia e homocistinúria

Also Published As

Publication number Publication date
US20240058429A1 (en) 2024-02-22
WO2021242258A1 (en) 2021-12-02
CN117881418A (zh) 2024-04-12
AU2020449880A1 (en) 2023-01-19
JP2023535537A (ja) 2023-08-18
EP4157331A4 (en) 2024-01-24
KR20230047335A (ko) 2023-04-07
CA3180781A1 (en) 2021-12-02
BR112022024329A2 (pt) 2023-01-31
EP4157331A1 (en) 2023-04-05

Similar Documents

Publication Publication Date Title
WO2020086726A3 (en) Nerve stimulation for treating migraine and other headache conditions
MXPA05009044A (es) Metodos para utilizar celulas derivadas de tejido adiposo en el tratamiento de condiciones cardiovasculares.
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
EP2465923A3 (en) Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
MX2021010173A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso.
MX2023004156A (es) Terapia combinada para el tratamiento del cancer.
WO2018209022A3 (en) Methods of treating neuropsychiatric disorders
MX2022003194A (es) Tratamiento de deterioro del comportamiento en la encefalopatia del desarrollo y epileptica.
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
MX2023005591A (es) Metodos de tratamiento de enfermedades y trastornos.
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
ZA202104786B (en) Deutetrabenazine for the treatment of dyskinesia in cerebral palsy
MX2022005250A (es) Combinaciones terapeuticas de acalabrutinib y capivasertib para tratar neoplasias malignas de linfocitos b.
MX2021006778A (es) Metodo novedoso para el tratamiento del cancer mediante inmunomodulacion.
MX2021011529A (es) Chiauranib para el tratamiento de cáncer de pulmón microcítico.
MX2022015109A (es) Tratamiento de homocistinuria e hiperhomocisteinemia mediante el uso de cistationina-gamma-liasa.
MX2021003734A (es) Métodos de tratamiento del linfoma de linfocitos t periférico mediante terapia con conjugado fármaco-anticuerpo anti-cd30.
WO2023009834A3 (en) Methods of treating cancer
MX2023011790A (es) Terapias combinadas para tratar el cancer.
MX2023004881A (es) Inhibidores de pde9 para el tratamiento de insuficiencia cardíaca.
MX2021005189A (es) Uso de tivozanib para tratar sujetos con cancer refractario.
MX2023006551A (es) Tratamiento de las convulsiones refractarias.
MX2022003686A (es) Uso de inhibidores de fgfr en canceres geneticamente alterados para mejorar la respuesta de los pacientes a los inhibidores de puntos de control inmunitarios en entornos de tratamiento secuencial.
PH12021550417A1 (en) Compositions and methods for controlled ovarian stimulation
WO2019241742A8 (en) Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer